Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 1,100,000 shares, a decline of 6.0% from the January 15th total of 1,170,000 shares. Currently, 5.0% of the shares of the company are sold short. Based on an average trading volume of 60,300 shares, the short-interest ratio is presently 18.2 days.

Analysts Set New Price Targets

Several analysts have recently weighed in on ACRV shares. BMO Capital Markets lowered their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Acrivon Therapeutics in a report on Thursday, November 14th. Cantor Fitzgerald started coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They issued an "overweight" rating on the stock. Finally, KeyCorp assumed coverage on shares of Acrivon Therapeutics in a report on Friday, January 31st. They issued an "overweight" rating on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $23.67.

Institutional Trading of Acrivon Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ACRV. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Acrivon Therapeutics by 29.7% in the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company's stock valued at $619,000 after purchasing an additional 23,535 shares in the last quarter. Corton Capital Inc. purchased a new stake in shares of Acrivon Therapeutics in the fourth quarter valued at about $73,000. Acorn Capital Advisors LLC purchased a new stake in shares of Acrivon Therapeutics in the fourth quarter valued at about $2,440,000. Northern Trust Corp lifted its holdings in shares of Acrivon Therapeutics by 11.3% in the fourth quarter. Northern Trust Corp now owns 117,323 shares of the company's stock valued at $706,000 after purchasing an additional 11,925 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Acrivon Therapeutics by 20.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company's stock valued at $223,000 after purchasing an additional 6,239 shares in the last quarter. Hedge funds and other institutional investors own 71.62% of the company's stock.

Acrivon Therapeutics Stock Performance

ACRV stock traded down $0.31 during trading on Friday, reaching $5.54. 40,699 shares of the company were exchanged, compared to its average volume of 57,185. The company has a market cap of $172.52 million, a P/E ratio of -2.05 and a beta of 0.77. Acrivon Therapeutics has a 52-week low of $3.75 and a 52-week high of $11.90. The stock's 50 day moving average price is $5.93 and its 200 day moving average price is $7.12.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.